Kyverna Initiates Rolling BLA Submission for Autoimmune CAR T Therapy

Event summary

  • Kyverna initiated a rolling BLA submission for miv-cel in stiff person syndrome (SPS) after FDA alignment on a single-arm trial.
  • Primary analysis of the KYSA-8 trial showed robust, durable effects in SPS with no approved therapies.
  • Phase 3 trial enrollment advances in generalized myasthenia gravis (gMG) with Phase 2 data showing durable efficacy out to one year.
  • Kyverna reported $236.4 million in cash as of March 31, 2026, with a net loss of $39.7 million for Q1 2026.

The big picture

Kyverna's rolling BLA submission for miv-cel marks a significant milestone in the autoimmune CAR T therapy space, positioning the company as a leader in developing durable, drug-free remission treatments. The strategic focus on neuroimmunology and the alignment with the FDA underscore Kyverna's potential to reshape the treatment paradigm for debilitating autoimmune diseases. With a strong cash position and advancing clinical trials, Kyverna is poised to establish a multi-indication franchise, reinforcing its leadership in autoimmune cell therapies.

What we're watching

Regulatory Pathway
Whether the FDA's alignment on a single-arm trial will expedite miv-cel's approval and priority review under RMAT designation.
Commercial Execution
How Kyverna's appointment of Nadia Dac as Chief Commercial Officer will impact its launch readiness for miv-cel in SPS.
Clinical Pipeline
The pace at which Kyverna can advance its Phase 3 trial in gMG and report additional data from its Phase 1 IIT study in PMS.